التفاصيل البيبلوغرافية
| العنوان: |
Cancer and Myotonic Dystrophy. |
| المؤلفون: |
D'Ambrosio, Eleonora S.1 (AUTHOR), Gonzalez-Perez, Paloma2 (AUTHOR) pgonzalezperez@partners.org |
| المصدر: |
Journal of Clinical Medicine. Mar2023, Vol. 12 Issue 5, p1939. 14p. |
| مصطلحات موضوعية: |
*MYOTONIA atrophica, *SPINOCEREBELLAR ataxia, *PATIENT compliance, *MUSCULAR dystrophy, *EARLY detection of cancer, *MEDICAL screening |
| مستخلص: |
Myotonic dystrophy (DM) is the most common muscular dystrophy in adults. Dominantly inherited CTG and CCTG repeat expansions in DMPK and CNBP genes cause DM type 1 (DM1) and 2 (DM2), respectively. These genetic defects lead to the abnormal splicing of different mRNA transcripts, which are thought to be responsible for the multiorgan involvement of these diseases. In ours and others' experience, cancer frequency in patients with DM appears to be higher than in the general population or non-DM muscular dystrophy cohorts. There are no specific guidelines regarding malignancy screening in these patients, and the general consensus is that they should undergo the same cancer screening as the general population. Here, we review the main studies that investigated cancer risk (and cancer type) in DM cohorts and those that researched potential molecular mechanisms accounting for DM carcinogenesis. We propose some evaluations to be considered as malignancy screening in patients with DM, and we discuss DM susceptibility to general anesthesia and sedatives, which are often needed for the management of cancer. This review underscores the importance of monitoring the adherence of patients with DM to malignancy screenings and the need to design studies that determine whether they would benefit from a more intensified cancer screening than the general population. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder